Supernus Pharmaceuticals’ first quarter results were met with a negative market reaction, despite revenue and non-GAAP profit ...

Annabel Samimy (Stifel): Sought details on ONAPGO’s reimbursement and product differentiation versus AbbVie’s competing pump. Khattar highlighted ONAPGO’s unique mechanism and support services, ...

Supernus is buying Sage Therapeutics for $561 million, hoping that it can transform a new postpartum depression drug into a standard of care.

Supernus believes that with Zurzuvae joining its three other key growth products, Qelbree, ONAPGO, and GOCOVRI, the company is poised for significant future growth.

Last quarter, Supernus also launched ONAPGO (apomorphine hydrochloride injection), a pump to aid delivery of APOKYN, which was finally approved by the FDA at the fourth time of asking, and which ...

Sage Therapeutics has agreed to be acquired by Supernus Pharmaceuticals for up to $795 million, marking a “good end” to the biotech’s story, according to analysts. The deal comes about five months ...

Jack Khattar, President and CEO of Supernus Pharmaceuticals, said the acquisition augments the company’s growth profile by adding a fourth growth product to its portfolio, in addition to Qelbree, ...

Combined with its three other growth products (Qelbree ®, ONAPGO TM, and GOCOVRI ®), Supernus believes it is poised for significant future growth. Augments Supernus central nervous system (CNS ...